Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry.
Nevin HammamMichael EvansChristopher F BellKerry GairyRebecca GraingerGabriela SchmajukPublished in: ACR open rheumatology (2022)
This study showed reductions in mean daily glucocorticoid dose after belimumab initiation. Several limitations of EHRs for real-world effectiveness research were identified, which limited interpretation of results and may inform future study designs.